Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Matrixx Bought By Private Equity Firm H.I.G., Settles Personal Injury Lawsuits

This article was originally published in The Tan Sheet

Executive Summary

Matrixx Initiatives announced Dec. 14 private equity firm H.I.G. Capital will acquire the Scottsdale, Ariz.-based maker of Zicam cough/cold products for approximately $75.2 million.

You may also be interested in...



Zicam Marketer Matrixx Tabs Another Pharma Consumer Health Veteran As CEO

Private equity firm Gryphon Investments appoints Marc Rovner, with executive experience at Pfizer, Reckitt, Unilever and BI, to helm the Zicam brand homeopathic cold remedy marketer in a shakeup that also puts consumer health care industry veterans at lead posts for sales, marketing and strategy.

Zicam Marketer Matrixx Tabs Another Pharma Consumer Health Veteran As CEO

Private equity firm Gryphon Investments appoints Marc Rovner, with executive experience at Pfizer, Reckitt, Unilever and BI, to helm the Zicam brand homeopathic cold remedy marketer in a shakeup that also puts consumer health care industry veterans at lead posts for sales, marketing and strategy.

H.I.G.’s Capstone Puts Customers First With Custom Formulations

The private equity firm’s H.I.G. Growth Partners capital investment affiliate merges two of its businesses, Integrity Nutraceuticals and Cornerstone Research & Development, into Capstone Nutrition. CEO Greg Horn says “we really occupy a niche” in “a pretty fragmented industry” with custom formulations for every product.

Related Content

Topics

UsernamePublicRestriction

Register

PS104755

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel